Hyperhomocysteinemia is detrimental to pregnancy in mice and is associated with preterm birth

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1832, Issue 8, 2013, Pages 1149-1158

  Sonne, S R ^a   Bhalla, V K ^a   Barman, S A ^a   White, R E ^a   Zhu, S ^a   Newman, T M ^a   Prasad, P D ^a   Smith, S B ^a   Offermanns, S ^b   Ganapathy, V ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

Author keywords

Cyclooxygenase 2; Homocysteine; Niacin receptor; Preterm birth; Prostaglandin E2

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYSTATHIONINE BETA SYNTHASE; GPR 109A; HOMOCYSTEINE; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; OXYTOCIN RECEPTOR; PROSTAGLANDIN E2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LINE; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE EXPRESSION; HETEROZYGOTE; HUMAN; HUMAN CELL; HYPERHOMOCYSTEINEMIA; IN VITRO STUDY; MOUSE; MYOMETRIUM; NONHUMAN; PATCH CLAMP; PLACENTA; PREGNANCY; PREMATURE LABOR; PRIORITY JOURNAL; TROPHOBLAST; UPREGULATION; UTERUS CONTRACTION; WILD TYPE;

ANIMALS; CELL LINE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYSTATHIONINE BETA-SYNTHASE; DINOPROSTONE; FEMALE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; LARGE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNEL ALPHA SUBUNITS; MICE; MICE, INBRED C57BL; MUSCLE CONTRACTION; MYOMETRIUM; PLACENTA; PREGNANCY; PREGNANCY COMPLICATIONS; PREMATURE BIRTH; RECEPTORS, NICOTINIC; RECEPTORS, OXYTOCIN; TROPHOBLASTS; UP-REGULATION; UTERUS;

EID: 84877324313     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2013.04.006     Document Type: Article

References (42)

1. Goldenberg R.L. The management of preterm labor. Obstet. Gynecol. 2002, 100:1020-1037.
2. Smith G.C., Shah I., White I.R., Pell J.P., Crossley J.A., Dobbie R. Maternal and biochemical predictors of spontaneous preterm birth among nulliparous women: a systematic analysis in relation to the degree of prematurity. Int. J. Epidemiol. 2006, 35:1169-1177.
3. Kramer M.S., Kahn S.R., Rozen R., Evans R., Platt R.W., Chen M.F., Goulet L., Seguin L., Dassa C., Lydon J., McNamara H., Dahhou M., Genest J. Vasculopathic and thrombophilic risk factors for spontaneous preterm birth. Int. J. Epidemiol. 2009, 38:715-723.
4. Strauss K.A., Morton D.H., Puffenberger E.G., Hendrickson C., Robinson D.L., Wagner C., Stabler S.P., Allen R.H., Chwatko G., Jakubowski H., Niculescu M.D., Mudd S.H. Prevention of brain disease from severe 5,10-methylenetetrahydrofolate reductase deficiency. Mol. Genet. Metab. 2007, 91:165-175.
5. Maron B.A., Loscalzo J. The treatment of hyperhomocysteinemia. Annu. Rev. Med. 2009, 60:39-54.
6. Malinow M.R., Bostom A.G., Krauss R.M. Homocyst(e)ine, diet and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1999, 99:178-182.
7. Picciano M.F. Is homocysteine a biomarker for identifying women at risk of complications and adverse pregnancy outcomes?. Am. J. Clin. Nutr. 2000, 71:857-858.
8. Kalhan S. Metabolism of methionine in vivo: impact of pregnancy, protein restriction, and fatty liver disease. Emerging societies coexistence of childhood malnutrition and obesity. Nestle Nutr. Workshop Ser. Pediatr. Program. 2009, 63:121-131.
9. Watanabe M., Osada J., Aratani Y., Kluckman K., Reddick R., Malinow M.R., Maeda N. Mice deficient in cystathionine β-synthase: animal models for mild and severe homocyst(e)inemia. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:1585-1589.
10. Tunaru S., Kero J., Schaub A., Wufka C., Blaukat A., Pfeffer K., Offermanns S. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat. Med. 2003, 9:352-355.
11. Nelson D.M., Smith S.D., Furesz T.C., Sadovsky Y., Ganapathy V., Parvin C.A., Smith C.H. Hypoxia reduces expression and function of system A amino acid transporters in cultured term human trophoblasts. Am. J. Physiol. Cell Physiol. 2003, 284:C310-C315.
12. Barman S.A. Vasoconstrictor effect of endothelin-1 on hypertensive pulmonary arterial smooth muscle involves Rho-kinase and protein kinase C. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007, 293:L472-L479.
13. Aguilar H.N., Mitchell B.F. Physiological pathways and molecular mechanisms regulating uterine contractility. Hum. Reprod. Update 2010, 16:725-744.
14. Pérez G.J., Toro L., Erulkar S.D., Stefani E. Characterization of large conductance calcium-activated potassium channels from human myometrium. Am. J. Obstet. Gynecol. 1993, 168:652-660.
15. Anwer K., Oberti C., Perez G.J., Perez-Reyes N., McDougall J.K., Monga M., Sanborn B.M., Stefani E., Toro L. Calcium-activated K1 channels as modulators of human myometrial contractile activity. Am. J. Physiol. 1993, 265:C976-C985.
16. Khan R.N., Smith S.K., Morrison J.J., Ashford M.L. Ca2+-dependence and pharmacology of large-conductance K1 channels in non-labor and labor uterine myocytes. Am. J. Physiol. 1997, 273:Cl721-C1731.
17. Hanson J., Gille A., Zwykiel S., Lukasova M., Clausen B.E., Ahmed K., Tunaru S., Wirth A., Offermanns S. Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice. J. Clin. Invest. 2010, 120:2910-2919.
18. Gille A., Bodor E.T., Ahmed K., Offermanns S. Nicotinic acid: pharmacological effects and mechanisms of action. Annu. Rev. Pharmacol. Toxicol. 2008, 48:79-106.
19. McCully K.S. Homocysteine, vitamins, and vascular disease prevention. Am. J. Clin. Nutr. 2007, 86:1563S-1568S.
20. Cook J.W., Taylor L.M., Orloff S.L., Landry G.J., Moneta G.L., Porter J.M. Homocysteine and arterial disease: experimental mechanisms. Vascul. Pharmacol. 2002, 38:293-300.
21. Raijmakers T.M.M., Roes E.M., Poston L., Steegers A.P.E., Peters H.M.W. The transient increase of oxidative stress during normal pregnancy is higher and persists after delivery in women with pre-eclampsia. Eur. J. Obstet. Gynecol. Reprod. Biol. 2008, 138:39-44.
22. Lappas M. Visfatin regulates the terminal processes of human labour and delivery via activation of the nuclear factor-kB pathway. Mol. Cell. Endocrinol. 2012, 348:128-134.
23. Dayal S., Lentz S.R. Murine models of hyperhomocysteinemia and their vascular phenotypes. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1596-1605.
24. Chen Z., Karaplis A.C., Ackerman S.L., Pogribny I.P., Melnyk S., Lussier-Cacan S., Chen M.F., Pai A., John S.W., Smith S.S., Bottiglieri T., Bagley P., Selhub J., Rudnicki M.A., James S.J., Roze R. Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum. Mol. Genet. 2001, 10:433-443.
25. Swanson D.A., Liu M.L., Baker P.J., Garrett L., Stitzel M., Wu J., Harris M., Banerjee R., Shane B., Brody L.C. Targeted disruption of the methionine synthase gene in mice. Mol. Cell. Biol. 2001, 21:1058-1065.
26. Perla-Kajan J., Twardowski T., Jakubowski H. Mechanisms of homocysteine toxicity in humans. Amino Acids 2007, 32:561-572.
27. Toohey J.I. Homocysteine toxicity in connective tissue: theories, old and new. Connect. Tissue Res. 2008, 49:57-61.
28. Yap S. Classical homocystinuria: vascular risk and its prevention. J. Inherit. Metab. Dis. 2003, 26:259-265.
29. Poddar R., Sivasubramanian N., DiBello P.M., Robinson K., Jacobsen D.W. Homocysteine induces expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human aortic endothelial cells: Implications for vascular disease. Circulation 2001, 103:2717-2723.
30. Keating A.K., Freehauf C., Jiang H., Brodsky G.L., Stabler S.P., Allen R.H., Graham D.K., Thomas J.A., Van Hove J.L., Maclean K.N. Constitutive induction of pro-inflammatory and chemotactic cytokines in cystathionine beta-synthase deficient homocystinuria. Mol. Genet. Metab. 2011, 103:330-337.
31. Solini A., Santini E., Nannipieri M., Ferrannini E. High glucose and homocysteine synergistically affect the metalloproteinases-tissue inhibitors of metalloproteinases pattern, but not TGFβ expression, in human fibroblasts. Diabetologia 2006, 49:2499-2506.
32. Tyagi N., Gillespie W., Vacek J.C., Sen U., Tyagi S.C., Lominadze D. Activation of GABA-A receptor ameliorates homocysteine-induced MMP-9 activation by ERK pathway. J. Cell. Physiol. 2009, 220:257-266.
33. Bloomfield F.H., Oliver M.H., Hawkins P., Campbell M., Phillips D.J., Gluckman P.D., Challis J.R., Harding JE J.E. A periconceptional nutritional origin for noninfectious preterm birth. Science 2003, 300:606.
34. Baumslag N., Edelstein T., Metz J. Reduction of incidence of prematurity by folic acid supplementation in pregnancy. Br. Med. J. 1970, 1:16-17.
35. Blot I., Papiernik E., Kaltwasser J.P., Werner E., Tchernia G. Influence of routine administration of folic acid and iron during pregnancy. Gynecol. Obstet. Invest. 1981, 12:294-304.
36. Shaw G.M., Carmichael S.I., Nelson V., Selvin S., Schaffer D.M. Occurrence of low-birth weight and preterm delivery among California infants before and after compulsory food fortification with folic acid. Public Health Rep. 2004, 119:170-173.
37. Bukowski R., Malone F.D., Porter F.T., Nyberg D.A., Comstock C.H., Hankins G.D., Eddleman K., Gross S.J., Dugoff L., Craigo S.D., Timor-Tritsch I.E., Carr S.R., Wolfe H.M., D'Alton M.E. Periconceptional folate supplementation and the risk of spontaneous preterm birth: a cohort study. PLoS Med. 2009, 6:e1000061.
38. Callaway L., Colditz P.B., Fisk N.M. Folic acid supplementation and spontaneous preterm birth: adding grist to the mill?. PLoS Med. 2009, 6:e1000077.
39. Rozen R. Genetic modulation of homocysteinemia. Semin. Thromb. Hemost. 2000, 26:255-261.
40. Anderson C.A., Jorgensen A.L., Deeb S., McLerran D., Beresford S.A., Motulsky A.G. Equal proportion of adult male and female homozygous for the 677C→T mutation in the methylenetetrahydrofolate reductase polymorphism. Am. J. Med. Genet. 2005, 134A:97-99.
41. Facchinetti F., Vaccaro V. Pharmacological use of progesterone and 17-alpha-hydroxy progesterone caproate in the prevention of preterm delivery. Minerva Ginecol. 2009, 61:401-409.
42. Gupta S., Roman A.S. 17α-Hydroxyprogesterone caproate for the prevention of preterm birth. Womens Health 2012, 8:21-30.